![]() Karyopharm Therapeutics Karyopharm Therapeutics is a commercial-stage pharmaceutical company that pioneers in cancer therapies. | ![]() Blueprint Medicines Blueprint Medicines is a precision therapy company that invents medicines for people with cancer and blood disorders. | ![]() Agenus Agenus is an immuno-oncology company that focuses on the discovery and development of therapies for treating cancer. | ![]() Partner Therapeutics Partner Therapeutics is developing and commercializing cancer medicines and combination therapies. | ![]() Rakuten Medical Rakuten Medical (formerly Rakuten Aspyrian) is a clinical stage biotechnology company developing tumor-targeted precision therapies. | |
Founding Date | Founding Date 2008 | Founding Date 2011 | Founding Date 1994 | Founding Date 2017 | Founding Date 2013 |
Type | Type Public | Type Public | Type Public | Type Private | Type Private |
Tags | |||||
Locations | Locations Newton, US HQ Givatayim, IL | Locations Cambridge, US HQ Amsterdam, NL Lugano, CH Zug, CH | Locations Lexington, US HQ Cambridge, GB Emeryville, US Berkeley, US Vacaville, US | Locations Lexington, US HQ Boston, US Lynnwood, US | Locations San Diego, US HQ Setagaya City, JP Amsterdam, NL Ecublens, CH Taipei, TW Taipei, TW San Mateo, US |
Employees | Employees 32516% decrease | Employees 6552% increase | Employees 38927% decrease | Employees 1911% increase | Employees 1191% decrease |
Valuation ($) | Valuation ($) 111.7 m | Valuation ($) 5.3 b | Valuation ($) 96.2 m | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $146m (FY, 2023) | Revenue (est.) $249.4m (FY, 2023) | Revenue (est.) $156.3m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods $4.9m (FY, 2023) | Cost of goods $8.5m (FY, 2023) | Cost of goods $3.1m (FY, 2023) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $141.1m (FY, 2023) | Gross profit $240.8m (FY, 2023) | Gross profit $153.2m (FY, 2023) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($143.1m) (FY, 2023) | Net income ($507m) (FY, 2023) | Net income ($257.4m) (FY, 2023) | Net income N/A | Net income N/A |
Funding | |||||
Latest funding round | Latest funding round N/A | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 60m (about 7 years ago) | Latest funding round $ 100m (over 5 years ago) |
Total funding raised | Total funding raised $ 248.7m | Total funding raised $ 1.7b | Total funding raised $ 171.1m | Total funding raised $ 60m | Total funding raised $ 451.9m |
Blueprint Medicines is a precision therapy company that invents medicines for people with cancer and blood disorders.
View companyAgenus is an immuno-oncology company that focuses on the discovery and development of therapies for treating cancer.
View companyPartner Therapeutics is developing and commercializing cancer medicines and combination therapies.
View companyRakuten Medical (formerly Rakuten Aspyrian) is a clinical stage biotechnology company developing tumor-targeted precision therapies.
View company